Discussion  by unknown
Yasufuku et al General Thoracic Surgerymediastinal reassessment. The potential for repeat sampling
with relative ease is also possible with EBUS-TBNA,
because redo EBUS-TBNA is simpler and safer than redo
mediastinoscopy.13 Future studies will be needed to evalu-
ate the role of EBUS-TBNA and mediastinoscopy after in-
duction treatment.
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data management team at the Division of Thoracic Surgery,
Toronto General Hospital, University Health Network (Frances
Hui, Jennifer Lister, Judy Horneck) for contributions to the study.G
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Dr Joel Cooper (Philadelphia, Pa). I have no disclosures other
than great pride in one of my former institutions, the University of
Toronto.
Dr Yasufuku, congratulations on your membership this morning
to the American Association of Thoracic Surgery. I appreciate the
article, which I had a chance to review 1 week in advance, which
was outstanding.
I am convinced from the article and your presentation that you
have demonstrated equivalent ability to stage the mediastinum
with EBUS and mediastinoscopy. It was a well-designed and
very well-executed study, and the key features you pointed out
were well-trained thoracic surgeons who understand their anat-
omy, the use of general anesthesia in this particular series, and
outstanding cytopathology.
I have several questions I will ask one at a time. Are the results
you have presented regarding the correlation between EBUS and
mediastinoscopy based on the on-site sampling or were there cases
where the cell block and later final pathology changed the results?
If you achieved these results with on-site sampling, I want to know
how you did it, because we certainly cannot produce this degree of
accuracy with on our on-site diagnoses.
Dr Yasufuku. In terms of on-site cytology, we have compared
the results of on-site cytologic findings with the final findings from
the cell block, and in our 153 patients, there was no discrepancy
between the diagnosis of the ROSE cytology and the final cytol-
ogy. I may not have been clear, but for this study, some patients
went directly to resection after the mediastinoscopy and EBUS
and then some patients had their resection done a few days later.
In case the patient went directly to resection, the decision was
based on our findings on ROSE cytology and quick section from
lymph nodes sampled by mediastinoscopy.
It is an important issue about whether we can rely on the results
of ROSE cytology, and more important to be able to collaborate
with your cytopathologists. In our experience, we have learneddiovascular Surgery c Volume 142, Number 6 1399
General Thoracic Surgery Yasufuku et al
G
T
Sa lot by doing this study, because we get direct feedback from the
cytopathologist, and by doing that, we have been able to modify
how we sample our lymph nodes so that we can submit a better
sample.
Dr Cooper. Clearly, the significance that a person attaches to
the presence or absence of mediastinal lymph node involvement
will determine how vigorously he or she attempts to pursue the
goal that you achieved. What is your current policy on patients
with known or suspected lung cancer? How important is it to
you to obtain accurate mediastinal node sampling before thoracot-
omy, and what do you do with that information?
Dr Yasufuku. I think accurate mediastinal lymph node staging
is an important issue that affects patient outcome. In our current
practice, according to the results of our study, when patients
have a clinical N2 disease based on imaging, we would start out
the invasive staging with endobronchial ultrasound. We not only
sample 1 lymph node station, but, as I showed in this study, we typ-
ically do systematic lymph node sampling, not just going after
1 lymph node. Even if we do find metastasis in 1 lymph node,
we would also check the other mediastinal lymph node stations.
If we do confirm the disease and it is resectable, we would have
the patient undergo induction treatment. I think the beauty about
EBUS is that a redo EBUS is typically easier than a redo mediasti-
noscopy. So we can go back after induction treatment, follow-up
on these patients, and actually safely restage the patients. If neces-
sary, we can always do a mediastinoscopy as well.
Dr Cooper. Thank you, and that answered another question that
I had. Finally, do you obtain sufficient material for tumor markers,
which increasingly is important in directing the neoadjuvant
therapy of these patients?
Dr Yasufuku. Sometimes it may be a challenge, but if done in
the correct way, we have been able to obtain adequate samples for
molecular analysis, such as epidermal growth factor receptor mu-
tation analysis. Regular immunohistochemistry is done routinely
by the cytopathologist using the cell block, and the cytopathologist
is typically happy with what we submit.COMMEN
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1400 The Journal of Thoracic and Cardiovascular SurDr Frank Detterbeck (New Haven, Conn). Just a quick com-
ment. I think that EBUS is not EBUS is not EBUS, and mediasti-
noscopy is not mediastinoscopy. Certainly EBUS as you have done
it is different from what many people do; they quickly aspirate 1
node station and that is it, and the same with mediastinoscopy,
as Alex Little showed us in the United States in 2005, where
50% don’t even sample a single node. You have done a very sys-
tematic staging. Furthermore, video mediastinoscopy is better
than old-fashioned mediastinoscopy. It is important for us to con-
sider these results in this context as we figure out how to imple-
ment them more broadly.
Dr Bryan Meyers (St Louis, Mo). I enjoyed your article. It is
going to be an excellent contribution to the literature. The only
area where either of your treatment arms diverged from standard
clinical care was the use of a different needle at each site. Equip-
ment from Olympus was donated for the trial, and so it was okay.
We don’t have that same advantage during a case of routine clin-
ical care. How do you think that discrepancymight affect the inter-
pretation or generalizability of your results, and could you justify
why you chose to do that?
Dr Yasufuku. Thank you for raising an important issue. The
reason why we chose to use different needles was because we
wanted to eliminate contamination. I think we should ideally use
different needles for different lymph node stations, especially
when you do not have ROSE cytology where the cytopathologists
can tell you if the needle you used was positive for cancer or not.
We always start out our sampling from the N3 nodes and then work
our way to the N2 and N1 nodes. Needles cost approximately $80
to $100 each, but to prevent contamination and possible upstaging,
I think it is important to use different needles.
If you have ROSE cytologic evaluation and the lymph nodes
are found to be negative for malignancy, it may be possible to
use the same needle after washing the needle properly; however,
there have been no studies looking at the use of the same needle
for different lymph node stations and the impact on the final
diagnosis.TARYMediastinoscopy: An obsolete procedure?Valerie W. Rusch, MDFor approximately 50 years, mediastinoscopy has been
a pivotal part of the pretreatment staging of lung cancer.1
At one time, respected thoracic surgical groups in North
America and Europe considered mediastinoscopy manda-
tory before proceeding to resection of a non–small cell
lung cancer (NSCLC). However, during the past 30 years,
improvements in noninvasive imagingmodalities, first com-
puted tomography and then positron emission tomography,gery c December 2011
